CARDIOMYOPATHY
Relationship between plasma level of cardiotrophin-1 and left ventricular mass index in patients with dilated cardiomyopathy
Takayoshi Tsutamoto, MD*,*,
Atsuyuki Wada, MD*,
Keiko Maeda, MD*,
Naoko Mabuchi, MD*,
Masaru Hayashi, MD*,
Takashi Tsutsui, MD*,
Masato Ohnishi, MD*,
Masanori Fujii, MD*,
Takehiro Matsumoto, MD*,
Takashi Yamamoto, MD*,
Xinwen Wang, MD*,
Shigeru Asai, PhD ,
Tetsuo Tsuji, PhD,
Hitoshi Tanaka, PhD,
Yoshihiko Saito, MD ,
Koichiro Kuwahara, MD,
Kazuwa Nakao, MD and
Masahiko Kinoshita, MD*
* First Department of Internal Medicine, Shiga University of Medical Science, Otsu, Japan
Diagnostic Department, Shionogi & Co., Osaka, Japan
Department of Medicine and Clinical Science, Kyoto University Graduate School of Medicine, Kyoto, Japan
Manuscript received March 26, 2001;
revised manuscript received June 19, 2001,
accepted July 13, 2001.
* Reprint requests and correspondence: Dr. Takayoshi Tsutamoto, First Department of Internal Medicine, Shiga University of Medical Science, Seta-Tsukinowa, Otsu, 520-2192, Japan
tutamoto{at}belle.shiga-med.ac.jp
OBJECTIVES
The study evaluated the relationship between plasma cardiotrophin-1 (CT-1) concentration and left ventricular (LV) mass in dilated cardiomyopathy (DCM) patients with congestive heart failure (CHF).
BACKGROUND
Cardiotrophin-1 is a newly identified member of the interleukin-6 (IL-6) family of cytokines and one of the endogenous ligands for gp130 signaling pathways in the heart, and it has potent hypertrophic and survival effects on cardiac myocytes. However, the clinical significance of CT-1 is poorly understood.
METHODS
We measured the plasma CT-1 level in 51 consecutive patients with DCM. Patients were classified into two groups: small LV mass index group and large LV mass index group, based on the median level of LV mass index.
RESULTS
The plasma CT-1 level was increased in DCM patients with the severity of CHF and was significantly higher in the large LV mass group than in the small LV mass group, despite the absence of a difference in LV ejection fraction between the two groups. In addition, there was a significant positive correlation between the plasma CT-1 level and the LV mass index (r = 0.627, p < 0.0001). According to stepwise multivariate analyses among hemodynamic and neurohumoral factors, a high plasma CT-1 level showed an independent and significant positive relationship with a large LV mass index in patients with DCM.
CONCLUSIONS
These results indicate that the plasma CT-1 level is increased in patients with DCM and is significantly correlated with the LV mass index, suggesting that CT-1 plays an important role in structural LV remodeling in patients with DCM.
|
Abbreviations and Acronyms
| | ACE | = angiotensin-converting enzyme | | BNP | = brain natriuretic peptide | | CT-1 | = cardiotrophin-1 | | CHF | = congestive heart failure | | DCM | = dilated cardiomyopathy | | IL-6 | = interleukin-6 | | LV | = left ventricular | | LVEF | = left ventricular ejection fraction | | NYHA | = New York Heart Association |
|
This article has been cited by other articles:
|
|
|
|
 
A. Gonzalez, B. Lopez, S. Ravassa, J. Beaumont, T. Arias, N. Hermida, A. Zudaire, and J. Diez
Biochemical markers of myocardial remodelling in hypertensive heart disease
Cardiovasc Res,
February 15, 2009;
81(3):
509 - 518.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Natal, M. A. Fortuno, P. Restituto, A. Bazan, I. Colina, J. Diez, and N. Varo
Cardiotrophin-1 is expressed in adipose tissue and upregulated in the metabolic syndrome
Am J Physiol Endocrinol Metab,
January 1, 2008;
294(1):
E52 - E60.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Tsutamoto, S. Asai, T. Tanaka, H. Sakai, K. Nishiyama, M. Fujii, T. Yamamoto, M. Ohnishi, A. Wada, Y. Saito, et al.
Plasma level of cardiotrophin-1 as a prognostic predictor in patients with chronic heart failure
Eur J Heart Fail,
October 1, 2007;
9(10):
1032 - 1037.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. J. Pemberton, S. D. Raudsepp, T. G. Yandle, V. A. Cameron, and A. M. Richards
Plasma cardiotrophin-1 is elevated in human hypertension and stimulated by ventricular stretch
Cardiovasc Res,
October 1, 2005;
68(1):
109 - 117.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. H. Freed, R. H. Cunnington, A. L. Dangerfield, J. S. Sutton, and I. M.C. Dixon
Emerging evidence for the role of cardiotrophin-1 in cardiac repair in the infarcted heart
Cardiovasc Res,
March 1, 2005;
65(4):
782 - 792.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Chen and C. S. von Bartheld
Role of Exogenous and Endogenous Trophic Factors in the Regulation of Extraocular Muscle Strength during Development
Invest. Ophthalmol. Vis. Sci.,
October 1, 2004;
45(10):
3538 - 3545.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Toh, S. Kawashima, M. Kawai, T. Sakoda, T. Ueyama, S. Satomi-Kobayashi, S. Hirayama, and M. Yokoyama
Transplantation of cardiotrophin-1-expressing myoblasts to the left ventricular wall alleviates the transition from compensatory hypertrophy to congestive heart failure in Dahl salt-sensitive hypertensive rats
J. Am. Coll. Cardiol.,
June 16, 2004;
43(12):
2337 - 2347.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Wang
Fill a Gab(1) in Cardiac Hypertrophy Signaling: Search a Missing Link Between gp130 and ERK5 in Hypertrophic Remodeling in Heart
Circ. Res.,
August 8, 2003;
93(3):
186 - 188.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. C.H Ng, N. W Court, C. G dos Remedios, and M. A Bogoyevitch
Activation of signal transducer and activator of transcription (STAT) pathways in failing human hearts
Cardiovasc Res,
February 1, 2003;
57(2):
333 - 346.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
